Vistin Pharma (OB:VISTN) 16.5% Net Margin Tests Slowing Earnings Growth Narrative

Vistin Pharma (OB:VISTN) has come into Q1 2026 with a recent run of solid top and bottom line numbers, capped by Q4 2025 revenue of NOK110.7 million and basic EPS of NOK0.36, backed by trailing twelve month revenue of NOK452.3 million and EPS of NOK1.69. Over recent quarters the company has seen revenue move from NOK105.8 million in Q3 2024 to NOK117.7 million in Q2 2025, while quarterly EPS has ranged between NOK0.37 and NOK0.49. This gives investors a clear view of how earnings track alongside the revenue base. Against that backdrop, the latest results sit within a profile of expanding net profit margins and consistent profitability, which keeps the focus firmly on how sustainable those margins look from here.

See our full analysis for Vistin Pharma.

With the recent earnings numbers laid out, the next step is to set them against the most widely held narratives around Vistin Pharma to see which stories hold up and which assumptions get tested.

Curious how numbers become stories that shape markets? Explore Community Narratives

16.5% net margin puts profitability in focus

• Over the last 12 months Vistin generated net income of NOK74.8 million on NOK452.3 million of revenue, which works out to a 16.5% net profit margin compared with 14.6% a year earlier.
• What stands out for a bullish view is that five year earnings growth of 38.1% per year and trailing 12 month earnings growth of 19.1% sit alongside this 16.5% margin. However, the latest four quarterly net income figures between NOK16.1 million and NOK21.7 million show that profit per quarter still moves around, so anyone leaning bullish needs to reconcile the strong long term growth rate with these shorter term swings.

Growth cools from 38.1% to 19.1%

• Earnings grew 19.1% over the last year on a trailing basis compared with the longer term 5 year earnings growth rate of 38.1% per year. This means the most recent year grew at roughly half the rate of the longer multi year average.
• Critics who take a bearish angle point to that gap between 38.1% and 19.1% as a sign that the past five years may have been stronger than the latest 12 months, and the quarterly EPS run from NOK0.49 in Q1 2025 to NOK0.36 in Q4 2025 gives bears concrete numbers to argue that near term momentum looks softer than the multi year story, even though the company remains profitable throughout the period.
  • This view is reinforced by trailing 12 month EPS moving from NOK1.76 in Q3 2025 to NOK1.69 in Q4 2025, which shows that the most recent rolling year did not extend that five year 38.1% pace.
  • At the same time, the fact that EPS stayed above NOK1.38 on a trailing basis since Q3 2024 means the bearish case focuses more on slower growth than on any break in profitability.

On top of that slower earnings growth, some investors question how long the high growth story can last given the tighter spread between recent quarterly EPS and the trailing 12 month figure. This has brought more attention to the balance between past strength and present pace in the 🐻 Vistin Pharma Bear Case.

P/E of 13.2x and 6.76% yield raise valuation questions

• The shares trade at a trailing P/E of 13.2x versus a peer average of 33.5x and a European pharmaceuticals average of 21x. A DCF fair value of NOK46.34 compared with a NOK22.20 share price and a 6.76% dividend yield creates a wide gap between trailing valuation metrics and the payout level, especially given the dividend is not covered by free cash flow over the last 12 months.
• What is striking for anyone leaning bullish is that this combination of a 13.2x P/E, DCF fair value of NOK46.34 and NOK1.69 of trailing 12 month EPS heavily supports the idea that investors are paying a lower multiple than peers for a company with five years of profitability. Yet the weak free cash flow coverage of a 6.76% dividend forces that same bullish view to confront the possibility that part of the return is coming from a payout that has not been backed by cash generation over the period.
  • Bulls often highlight the gap between NOK22.20 and the DCF fair value of NOK46.34, but the flagged issue that free cash flow did not cover the dividend keeps the quality of that yield at the center of the debate.
  • The 16.5% net margin over the last year supports the view that the core business is profitable, yet the cash coverage question means bullish arguments need to separate earnings strength from cash distribution capacity.

For investors weighing those earnings, margin and payout trade offs, it can help to see how others frame the balance between growth and valuation in the Curious how numbers become stories that shape markets? Explore Community Narratives.

Next Steps

Don’t just look at this quarter; the real story is in the long-term trend. We’ve done an in-depth analysis on Vistin Pharma’s growth and its valuation to see if today’s price is a bargain. Add the company to your watchlist or portfolio now so you don’t miss the next big move.

If the mixed signals on growth, margins and dividends leave you undecided, move quickly from reading to checking the data yourself and pressure testing both sides of the argument with the 2 key rewards and 1 important warning sign.

See What Else Is Out There

The slower trailing 12 month earnings growth, softer recent EPS run and weak free cash flow coverage of the dividend highlight pressure on income quality and momentum.

If those dividend coverage concerns and pacing issues give you pause, broaden your search to income ideas backed by stronger cash support using the 474 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com